Literature DB >> 19931444

Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings.

R Douglas Bruce1.   

Abstract

The link between injection drug use and HIV has been extensively described. Despite worldwide prevention efforts, injection drug use continues to be a risk factor for HIV transmission and both HIV and injection drug use continues to spread across the globe. Although methadone has demonstrated multiple health benefits including the reduction in injection drug use and HIV acquisition, the utilisation of methadone in many areas of the world remains one of secondary, rather than primary, HIV prevention. As a result, many who finally begin methadone enter treatment having accumulated medical and mental health problems as a result of delayed treatment. Rapid access to treatment and a more aggressive policy that realizes that methadone can help reduce opioid drug use is necessary if methadone is effectively going to act as primary HIV prevention. To delay access to methadone only increases the probability that the individual will acquire an infectious disease that is more costly to the individual in terms of morbidity and mortality and more costly to society as a whole. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19931444      PMCID: PMC2839048          DOI: 10.1016/j.drugpo.2009.10.004

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  30 in total

1.  Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study.

Authors:  M Gossop; J Marsden; D Stewart; A Rolfe
Journal:  Drug Alcohol Depend       Date:  2000-11-01       Impact factor: 4.492

2.  Preventing AIDS in drug addicts in Amsterdam.

Authors:  E C Buning; R A Coutinho; G H van Brussel; G W van Santen; A W van Zadelhoff
Journal:  Lancet       Date:  1986-06-21       Impact factor: 79.321

3.  Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia.

Authors:  W Hall; S Darke; M Ross; A Wodak
Journal:  Addiction       Date:  1993-04       Impact factor: 6.526

4.  Narcotic addiction and methadone treatment in Hong Kong: lessons for the United States.

Authors:  R G Newman
Journal:  J Public Health Policy       Date:  1985-12       Impact factor: 2.222

5.  High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.

Authors:  Eric C Donny; Sharon L Walsh; George E Bigelow; Thomas Eissenberg; Maxine L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  2002-03-13       Impact factor: 4.530

6.  Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia.

Authors:  Nadia Abdala; John M Carney; Amanda J Durante; Nikolai Klimov; Dimitri Ostrovski; Anton M Somlai; Andrei Kozlov; Robert Heimer
Journal:  Int J STD AIDS       Date:  2003-10       Impact factor: 1.359

7.  The impact of methadone treatment on registered convictions and arrests in HIV-positive and HIV-negative men and women with one or more treatment periods.

Authors:  Marlene Stenbacka; Anders Leifman; Anders Romelsjö
Journal:  Drug Alcohol Rev       Date:  2003-03

8.  Needle sharing and high-risk sexual behaviors among IV drug users in Southern Thailand.

Authors:  A Saelim; A Geater; V Chongsuvivatwong; A Rodkla; G A Bechtel
Journal:  AIDS Patient Care STDS       Date:  1998-09       Impact factor: 5.078

9.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis.

Authors:  Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell
Journal:  Drug Alcohol Depend       Date:  2003-09-10       Impact factor: 4.492

10.  The dynamics of the human immunodeficiency virus epidemics in the south of Brazil: increasing role of injection drug users.

Authors:  Waleska Teixeira Caiaffa; Fernando Augusto Proietti; Anna Bárbara Carneiro-Proietti; Sueli Aparecida Mingoti; Denise Doneda; Denise Gandolfi; Angela Cristina Maia Reis
Journal:  Clin Infect Dis       Date:  2003-12-15       Impact factor: 9.079

View more
  36 in total

1.  Linking HIV-positive jail inmates to treatment, care, and social services after release: results from a qualitative assessment of the COMPASS Program.

Authors:  Amy Nunn; Alexandra Cornwall; Jeannia Fu; Lauri Bazerman; Helen Loewenthal; Curt Beckwith
Journal:  J Urban Health       Date:  2010-12       Impact factor: 3.671

2.  Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence.

Authors:  Ryan Schwarz; Alexei Zelenev; R Douglas Bruce; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2012-04-24

3.  Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study.

Authors:  Barrot H Lambdin; Frank Masao; Olivia Chang; Pamela Kaduri; Jessie Mbwambo; Ayoub Magimba; Norman Sabuni; R Douglas Bruce
Journal:  Clin Infect Dis       Date:  2014-05-22       Impact factor: 9.079

Review 4.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

Review 5.  Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups.

Authors:  Onyema Ogbuagu; R Douglas Bruce
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

Review 6.  HIV infection and risk of overdose: a systematic review and meta-analysis.

Authors:  Traci C Green; Samuel K McGowan; Michael A Yokell; Enrique R Pouget; Josiah D Rich
Journal:  AIDS       Date:  2012-02-20       Impact factor: 4.177

7.  Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania.

Authors:  Omary Ubuguyu; Olivia C Tran; Robert Douglas Bruce; Frank Masao; Cassian Nyandindi; Norman Sabuni; Sheryl McCurdy; Jessie Mbwambo; Barrot H Lambdin
Journal:  Int J Drug Policy       Date:  2016-03-11

8.  Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

Authors:  T Garimella; R Wang; W-L Luo; P Wastall; H Kandoussi; M DeMicco; R D Bruce; C Hwang; R Bertz; M Bifano
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

9.  Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.

Authors:  Cindy Bednasz; Amneris E Luque; Barry S Zingman; Margaret A Fischl; Barbara M Gripshover; Charles S Venuto; Jie Gu; Zekun Feng; Robin DiFrancesco; Gene D Morse; Qing Ma
Journal:  Curr Vasc Pharmacol       Date:  2016       Impact factor: 2.719

10.  Addressing the HIV/AIDS epidemic among Puerto Rican people who inject drugs: the need for a multiregion approach.

Authors:  Sherry Deren; Camila Gelpí-Acosta; Carmen E Albizu-García; Ángel González; Don C Des Jarlais; Salvador Santiago-Negrón
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.